189 related articles for article (PubMed ID: 29682188)
1. Imaging markers of response to combined BRAF and MEK inhibition in BRAF mutated vemurafenib-sensitive and resistant melanomas.
Acciardo S; Mignion L; Joudiou N; Bouzin C; Baurain JF; Gallez B; Jordan BF
Oncotarget; 2018 Mar; 9(24):16832-16846. PubMed ID: 29682188
[TBL] [Abstract][Full Text] [Related]
2. Synchronous BRAF(V600E) and MEK inhibition leads to superior control of murine melanoma by limiting MEK inhibitor induced skin toxicity.
Gadiot J; Hooijkaas AI; Deken MA; Blank CU
Onco Targets Ther; 2013; 6():1649-58. PubMed ID: 24348046
[TBL] [Abstract][Full Text] [Related]
3. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma.
Sanlorenzo M; Choudhry A; Vujic I; Posch C; Chong K; Johnston K; Meier M; Osella-Abate S; Quaglino P; Daud A; Algazi A; Rappersberger K; Ortiz-Urda S
J Am Acad Dermatol; 2014 Dec; 71(6):1102-1109.e1. PubMed ID: 25440439
[TBL] [Abstract][Full Text] [Related]
4. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition.
Jiang X; Zhou J; Giobbie-Hurder A; Wargo J; Hodi FS
Clin Cancer Res; 2013 Feb; 19(3):598-609. PubMed ID: 23095323
[TBL] [Abstract][Full Text] [Related]
5. Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients.
Goldinger SM; Zimmer L; Schulz C; Ugurel S; Hoeller C; Kaehler KC; Schadendorf D; Hassel JC; Becker J; Hauschild A; Dummer R;
Eur J Cancer; 2014 Jan; 50(2):406-10. PubMed ID: 24183461
[TBL] [Abstract][Full Text] [Related]
6. BRAF Targeting Sensitizes Resistant Melanoma to Cytotoxic T Cells.
Atay C; Kwak T; Lavilla-Alonso S; Donthireddy L; Richards A; Moberg V; Pilon-Thomas S; Schell M; Messina JL; Rebecca VW; Xiao M; Tan J; Zhang G; Weber JS; Herlyn M; Sarnaik AA; Gabrilovich DI
Clin Cancer Res; 2019 May; 25(9):2783-2794. PubMed ID: 30765391
[TBL] [Abstract][Full Text] [Related]
7. Vemurafenib resistance reprograms melanoma cells towards glutamine dependence.
Hernandez-Davies JE; Tran TQ; Reid MA; Rosales KR; Lowman XH; Pan M; Moriceau G; Yang Y; Wu J; Lo RS; Kong M
J Transl Med; 2015 Jul; 13():210. PubMed ID: 26139106
[TBL] [Abstract][Full Text] [Related]
8. Effects of Molecular Heterogeneity on Survival of Patients With
Wongchenko MJ; Ribas A; Ascierto PA; Dréno B; Maria di Giacomo A; Garbe C; Chang I; Hsu J; Rooney I; Lu W; Koeppen H; Larkin J; Yan Y; McArthur GA
JCO Precis Oncol; 2018 Nov; 2():1-18. PubMed ID: 35135126
[TBL] [Abstract][Full Text] [Related]
9. Combined HP
Farah C; Neveu MA; Yelek C; Bouzin C; Gallez B; Baurain JF; Mignion L; Jordan BF
Biomedicines; 2022 Mar; 10(3):. PubMed ID: 35327519
[TBL] [Abstract][Full Text] [Related]
10. Combined Therapy with Anti-PD1 and BRAF and/or MEK Inhibitor for Advanced Melanoma: A Multicenter Cohort Study.
Huynh S; Mortier L; Dutriaux C; Maubec E; Boileau M; Dereure O; Leccia MT; Arnault JP; Brunet-Possenti F; Aubin F; Dreno B; Beylot-Barry M; Lebbe C; Lefevre W; Delyon J
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32585901
[TBL] [Abstract][Full Text] [Related]
11. Intermittent Versus Continuous Dosing of MAPK Inhibitors in the Treatment of BRAF-Mutated Melanoma.
Reger de Moura C; Vercellino L; Jouenne F; Baroudjian B; Sadoux A; Louveau B; Delyon J; Serror K; Goldwirt L; Merlet P; Bouquet F; Battistella M; Lebbé C; Mourah S
Transl Oncol; 2020 Feb; 13(2):275-286. PubMed ID: 31874374
[TBL] [Abstract][Full Text] [Related]
12. mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition.
Xue G; Kohler R; Tang F; Hynx D; Wang Y; Orso F; Prêtre V; Ritschard R; Hirschmann P; Cron P; Roloff T; Dummer R; Mandalà M; Bichet S; Genoud C; Meyer AG; Muraro MG; Spagnoli GC; Taverna D; Rüegg C; Merghoub T; Massi D; Tang H; Levesque MP; Dirnhofer S; Zippelius A; Hemmings BA; Wicki A
Oncotarget; 2017 Sep; 8(41):69204-69218. PubMed ID: 29050198
[TBL] [Abstract][Full Text] [Related]
13. Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors.
Stones CJ; Kim JE; Joseph WR; Leung E; Marshall ES; Finlay GJ; Shelling AN; Baguley BC
Front Genet; 2013; 4():66. PubMed ID: 23658559
[TBL] [Abstract][Full Text] [Related]
14. BRAF Inhibitor Resistance Confers Increased Sensitivity to Mitotic Inhibitors.
Misek SA; Foda BM; Dexheimer TS; Akram M; Conrad SE; Schmidt JC; Neubig RR; Gallo KA
Front Oncol; 2022; 12():766794. PubMed ID: 35444937
[TBL] [Abstract][Full Text] [Related]
15. Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction.
Moriceau G; Hugo W; Hong A; Shi H; Kong X; Yu CC; Koya RC; Samatar AA; Khanlou N; Braun J; Ruchalski K; Seifert H; Larkin J; Dahlman KB; Johnson DB; Algazi A; Sosman JA; Ribas A; Lo RS
Cancer Cell; 2015 Feb; 27(2):240-56. PubMed ID: 25600339
[TBL] [Abstract][Full Text] [Related]
16. Safety of BRAF+MEK Inhibitor Combinations: Severe Adverse Event Evaluation.
Meirson T; Asher N; Bomze D; Markel G
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32580351
[No Abstract] [Full Text] [Related]
17. BRAF/EZH2 Signaling Represses miR-129-5p Inhibition of SOX4 Thereby Modulating BRAFi Resistance in Melanoma.
Gebhardt K; Edemir B; Groß E; Nemetschke L; Kewitz-Hempel S; Moritz RKC; Sunderkötter C; Gerloff D
Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34063443
[TBL] [Abstract][Full Text] [Related]
18. Targeting the PI3K/AKT/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor.
Caporali S; Alvino E; Lacal PM; Levati L; Giurato G; Memoli D; Caprini E; Antonini Cappellini GC; D'Atri S
Int J Oncol; 2016 Sep; 49(3):1164-74. PubMed ID: 27572607
[TBL] [Abstract][Full Text] [Related]
19. Non-invasive in vivo imaging of early metabolic tumor response to therapies targeting choline metabolism.
Mignion L; Danhier P; Magat J; Porporato PE; Masquelier J; Gregoire V; Muccioli GG; Sonveaux P; Gallez B; Jordan BF
Int J Cancer; 2016 Apr; 138(8):2043-9. PubMed ID: 26595604
[TBL] [Abstract][Full Text] [Related]
20. A proof-of-concept study of sequential treatment with the HDAC inhibitor vorinostat following BRAF and MEK inhibitors in BRAFV600mutated melanoma.
Embaby A; Huijberts SCFA; Wang L; Leite de Oliveira R; Rosing H; Nuijen B; Sanders J; Hofland I; van Steenis C; Kluin RJC; Lieftink C; Smith CG; Blank CU; van Thienen JV; Haanen JBAG; Steeghs N; Opdam FL; Beijnen JH; Huitema ADR; Bernards R; Schellens JHM; Wilgenhof S
Clin Cancer Res; 2024 May; ():. PubMed ID: 38739109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
